Published online Nov 14, 2009. doi: 10.3748/wjg.15.5321
Revised: September 2, 2009
Accepted: September 9, 2009
Published online: November 14, 2009
AIM: To estimate the prevalence of celiac disease (CD) in adult patients with presumed irritable bowel syndrome (IBS).
METHODS: Between March 2005 and December 2008, 742 consecutive patients (293 male, median age 43 years, range 18-69 years) fulfilling the Rome II criteria for IBS were prospectively enrolled in the study. IBS was diagnosed via self-completed Rome II modular questionnaires. Anti-tissue transglutaminase (anti-tTG) serology was checked to initially recognize possible CD cases. Patients with a positive test were offered endoscopic duodenal biopsy to confirm the diagnosis of CD.
RESULTS: Thirty two patients (15 male, median age 41 years, range 19-59 years) were found to have organic diseases other than CD. Twenty four patients tested positive for anti-tTG antibodies, and duodenal biopsies confirmed the diagnosis in all of them. Thus, in this patient population with presumed IBS, 3.23% actually had CD.
CONCLUSION: CD is common in patients with presumed IBS. Routine screening for CD in patients with symptoms of IBS is recommended.
- Citation: Jadallah KA, Khader YS. Celiac disease in patients with presumed irritable bowel syndrome: A case-finding study. World J Gastroenterol 2009; 15(42): 5321-5325
- URL: https://www.wjgnet.com/1007-9327/full/v15/i42/5321.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.5321
| Type | Intraepithelial lymphocytes per 100 enterocytes | Crypts | Villi |
| 0 | < 40 | Normal | Normal |
| 1 | > 40 | Normal | Normal |
| 2 | > 40 | Increased | Normal |
| 3a | > 40 | Increased | Mild atrophy |
| 3b | > 40 | Increased | Marked atrophy |
| 3c | > 40 | Increased | Absent |
| IBS type | Gender | Total | |
| Male | Female | ||
| C-IBS | 140 (47.8) | 217 (48.3) | 357 (48.1) |
| D-IBS | 84 (28.7) | 122 (27.2) | 206 (27.8) |
| C/D-IBS | 69 (23.5) | 110 (24.5) | 179 (24.1) |
| Total | 293 | 449 | 742 |
| Variable | n (%) |
| Gender | |
| Female | 13 (54.2) |
| Male | 11 (45.8) |
| Age (yr) | |
| 18-25 | 8 (33.3) |
| 26-35 | 8 (33.3) |
| 36-61 | 8 (33.3) |
| mean (SD) | 33.5 (11.5) |
| Body mass index, mean (SD) | 26.6 (3.5) |
| Duration of symptoms (mo), mean (SD) | 26.8 (18.1) |
| IBS type | |
| C-IBS | 6 (25.0) |
| D-IBS | 14 (58.3) |
| C/D-IBS | 4 (16.7) |
| Malabsorptive features | |
| Hypoalbuminemia | 2 (8.3) |
| Hypocalcemia | 2 (8.3) |
| Iron deficiency | 4 (16.7) |
| None | 16 (66.7) |
Irritable bowel syndrome (IBS) is a highly prevalent disorder. It is found in 10% to 20% of individuals using standard diagnostic tools such as the Rome II criteria[1].
Diagnostic approaches to suspected IBS rely on eliciting symptoms that satisfy specific criteria and performing limited tests to exclude organic diseases that produce similar symptoms[2].
IBS can sometimes be difficult to distinguish clinically from adult-onset celiac disease (CD)[3-8]. A broad spectrum of symptoms and signs may be associated with untreated CD. In fact, many patients - especially those presenting in adulthood - have minimal or atypical symptoms[5,7-10].
The recent development of highly sensitive and specific serologic assays for CD has led to the increased realisation that the disease is more common than it was believed[11-15]. This justifies the concern that some IBS-labeled patients may in fact have CD.
Reports of prevalence of CD in IBS patients from the Middle East are scanty.
We aimed to estimate the prevalence of CD in patients masquerading as IBS, and also to describe their clinical features.
Ethical approval of the study was obtained from the Institutional Review Board at King Abdullah University Hospital. The potential implication of a positive result for CD was explained to all participants, and their written consent was obtained.
The Rome II criteria for IBS were applied to 891 consecutive patients upon their first visit to our outpatient gastroenterology clinic in the period between March 2005 and December 2008. The inclusion criteria were: age greater than 18 years, fulfilling the Rome II criteria for IBS; condition not previously investigated; absence of lactose intolerance or giardiasis. The exclusion criteria were: history of gastrointestinal alarm symptoms or signs; unwillingness to be submitted to esophagogastroduodenoscopy and/or colonoscopy. Only 764 individuals were eligible to participate in the study, and 22 (2.9%) of these did not agree to sign a written consent and thus were excluded from the study.
Testing for anti-tissue transglutaminase (anti-tTG) serology was performed using the ORG 540A Anti-Tissue-Transglutaminase IgA (ORGENTEC Diagnostika GmbH®).
Quantitative IgA anti-tTG test was determined using the ELISA method. The sensitivity and specificity of this test in our laboratory was previously estimated at 98% and 96%, respectively (unpublished data). Patients with a positive test were submitted to duodenal biopsy to confirm the possibility of CD.
Other investigations included complete blood count, serum chemistry panel, erythrocyte sedimentation rate, thyroid function tests, occult blood stool testing, and stool analysis for ova and parasites. Additionally, patients with diarrhea were put on a 3-wk lactose-free diet to exclude lactose intolerance.
All patients older than 45 years or with a family history of colorectal cancer, and those with a positive occult stool blood test were submitted to colonoscopy to rule out structural disease. Furthermore, in patients with diarrhea random colonic biopsies were taken to rule out microscopic colitis.
Using a standard biopsy forceps, six specimens were taken from the second and third portion of the duodenum. All biopsies were reviewed independently by two histopathologists, and changes of CD were reported using the modified Marsh criteria (Table 1).
Data were analyzed using the Statistical Package for Social Sciences (SPSS, version 15). Continuous data were described using mean, median, standard deviation, and range wherever appropriate. Categorical variables were described using proportions. The 95% confidence interval (CI) was used to calculate the interval estimate of the prevalence of CD. Differences in prevalence rates according to different types of IBS were tested using χ2 test; a P-value of less than 0.05 was considered statistically significant.
This study included a total of 742 patients (293 males and 449 females). Their distribution according to gender and IBS type is shown in Table 2. Thirty two patients (15 males and 17 females) with a median age of 41 years (range 19-59 years) were found to have organic diseases other than CD [14 hypothyroidism, three microscopic colitis (two collagenous and one lymphocytic colitis), six lactose intolerance, three ulcerative colitis, and six Crohn’s disease]. Twenty four patients [14 diarrhea-predominant IBS (D-IBS), six constipation-predominant IBS (C-IBS), and four alternating constipation-diarrhea IBS (C/D-IBS) tested positive for anti-tTG]. The prevalence of CD in different types of IBS is summarized in Table 3. The prevalence of CD in patients with D-IBS (6.80%, 95% CI: 3.36, 10.23) was significantly higher than that in patients with C-IBS (1.68%, 95% CI: 0.35, 3.01). Duodenal biopsies confirmed the diagnosis in all 24 patients. The modified Marsh criteria (Table 1) were used for the grading of severity of histopathological changes. Among our CD patients, two had Marsh type 1, seven had Marsh type 3a, 10 had Marsh type 3b, and five had Marsh type 3c. Thus, in this patient population with presumed IBS, 3.23% (95% CI: 1.96-4.50) actually had CD. The age of patients with CD (13 females and 11 males) ranged from 18 to 61 years with a mean (SD) of 33.5 (11.5). About 58% of these patients belonged to the D-IBS type, while less than 17% had the C/D-IBS type.
The demographic and clinical features of CD patients are summarized in Table 4. Interestingly, only eight of the CD patients had signs of intestinal malabsorption on further laboratory testing, with iron deficiency being the most common abnormality. The duration of IBS symptoms before the diagnosis of CD ranged between 6 and 72 mo (average 26.8 mo). The body mass index (BMI) of our CD patients was surprisingly higher than the expected, with an average of 26.6. All patients diagnosed with CD were started on a gluten-free diet, with subsequent improvement of their IBS-like symptoms in periods ranging from 2 to 6 wk.
A high prevalence of CD in patients with presumed IBS was found in the present study. This implies that even with strict application of the Rome II criteria, IBS patients may have undetected CD. The majority of our CD patients had severe histopathological changes in duodenal specimens according to the modified Marsh criteria[16]. The advanced histopathological changes most probably reflect long-standing, untreated disease in our patient population.
The prevalence of CD in several recent population studies from North America ranged from 0.5% to 1%[17-19]. Studies in Europe have shown that up to 1% of the adult population may have CD[11]. In contrast to its high prevalence in Western countries, CD is considered rare in non-Western populations. However, recent studies from the Middle East, Africa and India showed prevalence as high as 7.6% in selected groups of patients[20-22]. To the best of our knowledge, studies on the prevalence of CD in adult Jordanians have never been carried out. A prevalence study of CD in thousands of blood donors in Jordan is being conducted by the authors of the present study. Based on an interim analysis of the data obtained thus far, a prevalence of one in 200 could be projected. Therefore, IBS patients would be 6.5 times more likely to have CD than the general population.
The diagnosing of CD is often delayed, perhaps owing to a failure to recognize the protean manifestations of this disease, especially in the adult population. Patients often have few or no gastrointestinal symptoms and can even be obese[5,8,10]. In fact, in the present study none of the patients had typical symptoms of CD, such as steatorrhea or weight loss, and the majority of them had an average BMI in the overweight range.
Previously regarded as a mainly childhood problem it is now recognized that CD affects mostly adults, with about one quarter of patients being diagnosed at over 60 years of age. In a study by Green et al[8], data obtained on 1138 people with biopsy-proven CD showed that the majority of individuals were diagnosed in their 4th to 6th decades. Our study showed that adult CD can manifest at any age. However, it appears that the Jordanian adult patient population tends to present at a relatively younger age, possibly because of differences in gene penetrance as well as a larger wheat consumption by Jordanians (135 kg/head year); data from the Department of Agriculture, Jordan).
Survey data in the United States indicate that the median time to diagnosis in CD patients is 12 mo, and that over 20% of patients have symptoms for 10 years before CD is suspected and diagnostic testing performed[5]. However, the true denominator of undiagnosed CD is not well defined, and evolving data from both Europe and the United States indicate that many adult CD patients probably remain undetected[6,11,23]. In our CD patient population the time to diagnosis ranged between 8 and 72 mo. The delay in diagnosis could be ascribed to the atypical manifestations of the disease, but we believe that limited access to tertiary health care centers in our country could be another contributing factor to the long lag time before diagnosis.
CD can present with a wide spectrum of insidious symptoms. These can mimic symptoms of IBS. Several studies have suggested that the incidence of CD in patients with presumed IBS is higher than that of the normal population. In their case-control study of 300 subjects fulfilling the Rome II criteria for IBS, Sanders and colleagues found that the patients were 7 times more likely to have biopsy-proven CD than matched controls[4]. Sixty six patients with IBS tested positive for the antibodies, and 4.6% had active CD as compared with 0.66% of the non-IBS matched controls. The authors concluded that patients who meet the Rome II criteria for IBS should be investigated routinely for CD. More recently, the same investigators reported a primary care-based cross-sectional study in which 1200 patients were recruited and evaluated serologically for CD[24]. The prevalence of CD in this population sample was 1%, while in the 123 participants with IBS the prevalence of CD was 3.3%. Once again, the authors recommended that a low threshold for serological screening of patients with IBS symptoms would be an optimal strategy.
In a recent primary care-based, multicenter study from North America, 976 subjects with symptoms or conditions known to be associated with CD, including IBS, were serologically tested for CD[25]. A diagnosis of CD was established in 22 patients, and thus the prevalence of CD in the serologically screened sample was 2.25%. The most frequent reasons for CD screening in these 22 cases were bloating (12/22), thyroid disease (11/22), IBS (7/22), unexplained chronic diarrhea (6/22), chronic fatigue (5/22), and constipation (4/22). The authors concluded that an active case-finding strategy in the primary care setting is an effective way to improve the diagnostic rate of CD. Of interest, the group of patients with IBS or symptoms of IBS - such as bloating, diarrhea, and constipation - constituted the largest proportion of screening-detected patients in their study.
Conversely, other investigators suggested that the prevalence of CD is not increased in patients with IBS symptoms. Locke III and colleagues recently published the results of a case-control study[26]. Using a self-completed questionnaire, the researchers evaluated 150 adult subjects, of whom 72 reported having symptoms of IBS and dyspepsia, and 78 controls who reported no gastrointestinal symptoms. The total number of individuals with CD in each group was surprisingly high: two out of 50 with IBS (4%), two out of 24 with dyspepsia (6%), and two of the 78 controls (2.6%). The researchers concluded that CD alone cannot explain the presence of IBS or dyspepsia in the subjects. The results of their study are interesting, but the sample size is probably not large enough to reach statistical significance.
Other studies suggested that the prevalence of CD in adult patients with IBS is not higher than that in the general population. Hin and colleagues conducted a case-finding study of CD in a primary care setting[27]. None of their 132 patients with IBS symptoms had positive results for CD, suggesting that CD rarely masquerades as IBS. Yet, we believe that this study is limited because of the small sample size.
It is arguable that, similar to IBS patients, other patients with various functional gastrointestinal disorders (i.e. functional dyspepsia) could have a higher prevalence of CD. In a recent study from Italy[28], the authors reported biopsy-proven CD in 2% of their 726 patients with presumed functional dyspepsia, and suggested that routine duodenal biopsy should be considered in all dyspeptic patients undergoing diagnostic esophagogastroduodenoscopy. The results of this Italian study are interesting, but we believe that further prevalence studies of CD in the functional dyspepsia population are needed to corroborate these results.
There are some limitations in the present study. First, IgA test was not checked for all patients, which could underestimate the prevalence of positive serology for CD because of the strict dependence of the anti-tTG test on the level of IgA. Second, because of limited resources, we used the lactose-free diet test to rule out lactose intolerance instead of the more accurate hydrogen breath test. Because of the lower sensitivity and specificity of the lactose-free diet test, some patients with lactose intolerance could be misdiagnosed as IBS or vice versa.
In conclusion, the prevalence of CD in patients with presumed IBS is high. Therefore, serological testing should be considered for all individuals with symptoms of IBS. However, larger, multicenter studies are needed to settle the debate on the utility - or futility - of screening IBS patients for CD.
Celiac disease (CD) may present with a broad spectrum of subtle or atypical symptoms. Some patients with irritable bowel syndrome (IBS) may have minimally symptomatic CD. The value of screening IBS patients for CD remains a matter of debate.
There were several early published studies showing minimal, atypical clinical presentations of CD. The widespread availability of highly sensitive and specific serologic tests for CD has allowed for large population-based serologic surveys that have shown this disorder to be very common, especially in at-risk groups such as patients with symptoms of IBS.
The present study underscores the importance of screening IBS patients for CD. The high prevalence of CD found in our large study population is in accordance with the findings of other investigators. However, scattered reports from different regions of the world assert that the prevalence of CD is not increased in patients believed to have IBS. Based on the results of our study, we believe that screening IBS patients for CD should be routinely performed.
Because the manifestations of CD respond to a gluten-free diet, testing for CD in patients with presumed IBS may prevent prolonged morbidity and unnecessary health care costs. The results of the present study may contribute to raising the awareness of the protean manifestations of CD, as well as settling the ongoing debate on the utility of screening IBS patients for CD. Larger, case-control studies of undetected CD in patients believed to have IBS are required to establish vigorous clinical guidelines for both primary care physicians and gastroenterologists.
CD is an immune-mediated enteropathy triggered by the ingestion of gluten-containing grains in genetically susceptible individuals. A case-finding study is a term used to describe a method which involves screening a smaller group of people for specific disorders based on specific baseline clinical characteristics.
The peer reviewers of this article believe that it is a valuable contribution to the pertinent literature. The study draws attention to the protean manifestations of CD and the need to be aware of this common disease in particular in conditions such as IBS.
Peer reviewer: Amado S Peña, Professor, Department of Pathology, Immunogenetics, VU University Medical Centre, De Boelelaan 1117, PO Box 7057, Amsterdam 1007 MB, The Netherlands
S- Editor Li LF L- Editor O'Neill M E- Editor Zheng XM
| 1. | Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, editors . Rome II. The functional gastrointesti- nal disorders: Diagnosis, pathophysiology and treatment: A Multinational consensus. 2nd ed. McLean, Va: Degnon and Associates 2000; . [Cited in This Article: ] |
| 2. | Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002;122:1701-1714. [Cited in This Article: ] |
| 3. | Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep. 2005;7:264-271. [Cited in This Article: ] |
| 4. | Sanders DS, Carter MJ, Hurlstone DP, Pearce A, Ward AM, McAlindon ME, Lobo AJ. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet. 2001;358:1504-1508. [Cited in This Article: ] |
| 5. | Zipser RD, Patel S, Yahya KZ, Baisch DW, Monarch E. Presentations of adult celiac disease in a nationwide patient support group. Dig Dis Sci. 2003;48:761-764. [Cited in This Article: ] |
| 6. | Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology. 2001;121:1329-1338. [Cited in This Article: ] |
| 7. | Bottaro G, Cataldo F, Rotolo N, Spina M, Corazza GR. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. Am J Gastroenterol. 1999;94:691-696. [Cited in This Article: ] |
| 8. | Green PHR, Stavropoulos SN, Panagi SG, Goldstein SL, Mcmahon DJ, Absan H, Neugut AI. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol. 2001;96:126-131. [Cited in This Article: ] |
| 9. | Makharia GK, Baba CS, Khadgawat R, Lal S, Tevatia MS, Madan K, Dattagupta S. Celiac disease: variations of presentations in adults. Indian J Gastroenterol. 2007;26:162-166. [Cited in This Article: ] |
| 10. | Lo W, Sano K, Lebwohl B, Diamond B, Green PH. Changing presentation of adult celiac disease. Dig Dis Sci. 2003;48:395-398. [Cited in This Article: ] |
| 11. | Catassi C, Fabiani E, Rätsch IM, Coppa GV, Giorgi PL, Pierdomenico R, Alessandrini S, Iwanejko G, Domenici R, Mei E. The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr Suppl. 1996;412:29-35. [Cited in This Article: ] |
| 12. | Reeves GE, Squance ML, Duggan AE, Murugasu RR, Wilson RJ, Wong RC, Gibson RA, Steele RH, Pollock WK. Diagnostic accuracy of coeliac serological tests: a prospective study. Eur J Gastroenterol Hepatol. 2006;18:493-501. [Cited in This Article: ] |
| 13. | Unsworth DJ, Brown DL. Serological screening suggests that adult coeliac disease is underdiagnosed in the UK and increases the incidence by up to 12%. Gut. 1994;35:61-64. [Cited in This Article: ] |
| 14. | Emami MH, Karimi S, Kouhestani S, Hashemi M, Taheri H. Diagnostic accuracy of IgA anti-tissue transglutaminase in patients suspected of having coeliac disease in Iran. J Gastrointestin Liver Dis. 2008;17:141-146. [Cited in This Article: ] |
| 15. | Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001;120:636-651. [Cited in This Article: ] |
| 16. | Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999;11:1185-1194. [Cited in This Article: ] |
| 17. | Dubé C, Rostom A, Sy R, Cranney A, Saloojee N, Garritty C, Sampson M, Zhang L, Yazdi F, Mamaladze V. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology. 2005;128:S57-S67. [Cited in This Article: ] |
| 18. | Not T, Horvath K, Hill ID, Partanen J, Hammed A, Magazzu G, Fasano A. Celiac disease risk in the USA: high prevalence of antiendomysium antibodies in healthy blood donors. Scand J Gastroenterol. 1998;33:494-498. [Cited in This Article: ] |
| 19. | Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, Elitsur Y, Green PH, Guandalini S, Hill ID. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163:286-292. [Cited in This Article: ] |
| 20. | Al Attas RA. How common is celiac disease in Eastern Saudi Arabia? Ann Saudi Med. 2002;22:315-319. [Cited in This Article: ] |
| 21. | al-Tawaty AI, Elbargathy SM. Coeliac disease in north-eastern Libya. Ann Trop Paediatr. 1998;18:27-30. [Cited in This Article: ] |
| 22. | Catassi C, Rätsch IM, Gandolfi L, Pratesi R, Fabiani E, El Asmar R, Frijia M, Bearzi I, Vizzoni L. Why is coeliac disease endemic in the people of the Sahara? Lancet. 1999;354:647-648. [Cited in This Article: ] |
| 23. | Mäki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, Ilonen J, Laurila K, Dahlbom I, Hansson T. Prevalence of Celiac disease among children in Finland. N Engl J Med. 2003;348:2517-2524. [Cited in This Article: ] |
| 24. | Sanders DS, Patel D, Stephenson TJ, Ward AM, McCloskey EV, Hadjivassiliou M, Lobo AJ. A primary care cross-sectional study of undiagnosed adult coeliac disease. Eur J Gastroenterol Hepatol. 2003;15:407-413. [Cited in This Article: ] |
| 25. | Catassi C, Kryszak D, Louis-Jacques O, Duerksen DR, Hill I, Crowe SE, Brown AR, Procaccini NJ, Wonderly BA, Hartley P. Detection of Celiac disease in primary care: a multicenter case-finding study in North America. Am J Gastroenterol. 2007;102:1454-1460. [Cited in This Article: ] |
| 26. | Locke GR 3rd, Murray JA, Zinsmeister AR, Melton LJ 3rd, Talley NJ. Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Mayo Clin Proc. 2004;79:476-482. [Cited in This Article: ] |
| 27. | Hin H, Bird G, Fisher P, Mahy N, Jewell D. Coeliac disease in primary care: case finding study. BMJ. 1999;318:164-167. [Cited in This Article: ] |
| 28. | Giangreco E, D'agate C, Barbera C, Puzzo L, Aprile G, Naso P, Bonanno G, Russo FP, Nicoletti A, Incarbone S. Prevalence of celiac disease in adult patients with refractory functional dyspepsia: value of routine duodenal biopsy. World J Gastroenterol. 2008;14:6948-6953. [Cited in This Article: ] |